Core Viewpoint - The company reported strong financial performance in 2024, with significant revenue growth and improved cash flow, indicating a solid operational foundation for future development [2][5]. Financial Performance - In 2024, the company achieved total revenue of 1.819 billion yuan, representing a year-on-year increase of 35.64% - The net profit attributable to shareholders was 220 million yuan, up 31.05% year-on-year - The non-recurring net profit reached 162 million yuan, reflecting a 39.58% increase year-on-year - Operating cash flow significantly increased to 320 million yuan, a remarkable growth of 103.99% year-on-year, marking a historical high [2]. Product Performance and Global Expansion - The injection molding products generated revenue of 909 million yuan, up 38.13% year-on-year, with a gross margin of 31.57% - Health products achieved revenue of 538 million yuan, a 42.83% increase year-on-year, although the gross margin decreased by 5.32% to 20.96% - Precision molds contributed 296 million yuan in revenue, a modest increase of 1.93%, with a gross margin of 39.49% - The company is expanding its overseas production capacity in Germany, Malaysia, Mexico, and Vietnam, positioning itself as one of the few domestic enterprises with a global production base [3]. R&D and Industry Applications - The company is focused on developing electronic skin technology, collaborating with AMBU to create plastic human skin for laboratory and educational use - The subsidiary, Yuke, has advanced IML technology and is developing IME technology, which can be applied to electronic and smart skin - Current products in the robotics sector include educational companion robots and automatic feeding robots, with samples of lightweight in-mold electronic products already developed [4]. Earnings Forecast - Revenue projections for 2025, 2026, and 2027 are 2.185 billion yuan, 2.691 billion yuan, and 3.192 billion yuan, respectively - Earnings per share (EPS) are forecasted to be 2.12 yuan, 2.54 yuan, and 3.01 yuan for the same years - The current stock price corresponds to price-to-earnings (PE) ratios of 27.6, 23.0, and 19.5, respectively, with a "buy" investment rating recommended [5].
唯科科技(301196)：现金流增速亮眼 海外产能可期